SEARCH

SEARCH BY CITATION

References

  • 1
    Bongartz LG, Cramer MJ, Braam B. The cardiorenal connection. Hypertension.2004;43:e14.
  • 2
    Bock JS, Gottlieb SS. Cardiorenal syndrome: new perspectives. Circulation.2010;121:25922600.
  • 3
    Noyez L, Plesiewicz I, Verheugt FW. Estimated creatinine clearance instead of plasma creatinine level as prognostic test for postoperative renal function in patients undergoing coronary artery bypass surgery. Eur J Cardiothorac Surg. 2006;29:461465.
  • 4
    Scrutinio D, Passantino A, Lagioia R, et al.Detection and prognostic impact of renal dysfunction in patients with chronic heart failure and normal serum creatinine. Int J Cardiol.2011;147:228233.
  • 5
    Gagliardi AC, Miname MH, Santos RD. Uric acid: a marker of increased cardiovascular risk. Atherosclerosis.2009;202:1117.
  • 6
    Kanbay M, Afsar B, Covic A. Uric acid as a cardiometabolic risk factor: to be or not to be. Contrib Nephrol.2011;171:6267.
  • 7
    Briguori C, Visconti G, Rivera NV, et al.Cystatin C and contrast-induced acute kidney injury. Circulation.2010;121:21172122.
  • 8
    Lassus JP, Nieminen MS, Peuhkurinen K, et al.Markers of renal function and acute kidney injury in acute heart failure: definitions and impact on outcomes of the cardiorenal syndrome. Eur Heart J.2010;31:27912798.
  • 9
    Tamariz L, Harzand A, Palacio A, et al.Uric acid as a predictor of all-cause mortality in heart failure: a meta-analysis. Congest Heart Fail.2011;17:2530.
  • 10
    Park HS, Kim H, Sohn JH, et al.Combination of uric acid and NT-proBNP: a more useful prognostic marker for short-term clinical outcomes in patients with acute heart failure. Korean J Intern Med.2010;25:253259.
  • 11
    Kilic T, Oner G, Ural E, et al.Comparison of the long-term prognostic value of cystatin C to other indicators of renal function, markers of inflammation and systolic dysfunction among patients with acute coronary syndrome. Atherosclerosis.2009;207:552558.
  • 12
    Campbell CY, Clarke W, Park H, et al.Usefulness of cystatin C and prognosis following admission for acute heart failure. Am J Cardiol.2009;104:389392.
  • 13
    Swedberg K, Cleland J, Dargie H, et al.Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:11151140.
  • 14
    Wasen E, Isoaho R, Mattila K, et al.Estimation of glomerular filtration rate in the elderly: a comparison of creatinine-based formulae with serum cystatin C. J Intern Med.2004;256:7078.
  • 15
    Jernberg T, Lindahl B, James S, et al.Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation.2004;110:23422348.
  • 16
    Urbonaviciene G, Shi GP, Urbonavicius S, et al.Higher cystatin C level predicts long-term mortality in patients with peripheral arterial disease. Atherosclerosis.2011;216:440445.
  • 17
    Kilic T, Oner G, Ural E, et al.Comparison of the long-term prognostic value of cystatin C to other indicators of renal function, markers of inflammation and systolic dysfunction among patients with acute coronary syndrome. Atherosclerosis.2009;207:552558.
  • 18
    Deo R, Fyr CL, Fried LF, et al.Kidney dysfunction and fatal cardiovascular disease – an association independent of atherosclerotic events: results from the Health, Aging, and Body Composition (Health ABC) study. Am Heart J.2008;155:6268.
  • 19
    Linzbach S, Samigullin A, Yilmaz S, et al.Role of N-terminal pro-brain natriuretic peptide and cystatin C to estimate renal function in patients with and without heart failure. Am J Cardiol.2009;103:11281133.
  • 20
    Comnick M, Ishani A. Renal biomarkers of kidney injury in cardiorenal syndrome. Curr Heart Fail Rep.2011;8:99105.
  • 21
    Xie L, Terrand J, Xu B. Cystatin C increases in cardiac injury: a role in extracellular matrix protein modulation. Cardiovasc Res. 2010;87:628635.
  • 22
    Werle B, Sauckel K, Nathanson CM, et al.Cystatins C, E/M and F in human pleural fluids of patients with neoplastic and inflammatory lung disorders. Biol Chem.2003;384:281287.
  • 23
    Shlipak MG, Katz R, Cushman M, et al.Cystatin-C and inflammatory markers in the ambulatory elderly. Am J Med.2005;118:1416 e25e31.
  • 24
    Reichlin T, Potocki M, Breidthardt T, et al.Diagnostic and prognostic value of uric acid in patients with acute dyspnea. Am J Med.2009;122:1054 e7e14.
  • 25
    Alimonda AL, Nunez J, Nunez E, et al.Hyperuricemia in acute heart failure. More than a simple spectator?Eur J Intern Med.2009;20:7479.
  • 26
    Manzano-Fernandez S, Boronat-Garcia M, Albaladejo-Oton MD, et al.Complementary prognostic value of cystatin C, N-terminal pro-B-type natriuretic peptide and cardiac troponin T in patients with acute heart failure. Am J Cardiol.2009;103:17531759.
  • 27
    Naruse H, Ishii J, Kawai T, et al.Cystatin C in acute heart failure without advanced renal impairment. Am J Med2009;122:566573.
  • 28
    Wu AH, Ghali JK, Neuberg GW, et al.Uric acid level and allopurinol use as risk markers of mortality and morbidity in systolic heart failure. Am Heart J.2010;160:928933.
  • 29
    Keller T, Messow CM, Lubos E, et al.Cystatin C and cardiovascular mortality in patients with coronary artery disease and normal or mildly reduced kidney function: results from the AtheroGene study. Eur Heart J.2009;30:314320.
  • 30
    Lassus J, Harjola VP, Sund R, et al.Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur Heart J. 2007;28:18411847.